E3 PreliminaryPreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
Gene expression profile of empirically delineated classes of unexplained chronic fatigue.
Carmel, Liran, Efroni, Sol, White, Peter D et al. · Pharmacogenomics · 2006 · DOI
Quick Summary
Researchers examined genes in blood samples from 111 women with unexplained chronic fatigue to see if different types of fatigue had different gene patterns. They used computer analysis to identify specific genes that were active or inactive in different fatigue groups. They found that certain genes were consistently different between fatigued and healthy people, while other genes only differed in specific fatigue subgroups.
Why It Matters
This study provides evidence that ME/CFS is not a single homogeneous condition but comprises distinct biological subtypes with different gene expression patterns, which could explain why patients respond differently to treatments. Identifying objective biomarkers through gene expression may eventually help clinicians diagnose ME/CFS more accurately and stratify patients for appropriate interventions.
Observed Findings
- Four genes (ZNF350, SLC1A6, FBX07, VAC14) consistently distinguished fatigued subjects from healthy controls across multiple fatigue classes.
- Two genes (PTCH2, TCL1A) were identified that differentiated specific subgroups of fatigued subjects rather than all fatigue classes.
- Principal component and latent class analyses delineated five and six distinct classes of unexplained chronic fatigue in the study population.
- A computational algorithm was successfully developed to identify discriminatory genes in multiclass expression problems.
Inferred Conclusions
- Unexplained chronic fatigue comprises biologically distinct subtypes with characteristic gene expression signatures.
- Some genes (e.g., ZNF350, SLC1A6) appear to be general fatigue biomarkers, while others are subtype-specific.
- Gene expression profiling may enable objective classification of fatigue phenotypes, particularly a subclass characterized by interoceptive dysfunction.
Remaining Questions
- Can these gene expression profiles be validated in an independent cohort and replicated across different populations (including males)?
- Do the identified gene expression patterns predict treatment response or disease prognosis?
- What are the biological mechanisms by which dysregulation of ZNF350, SLC1A6, FBX07, and VAC14 contributes to fatigue pathophysiology?
What This Study Does Not Prove
This study does not establish causation—differences in gene expression may be consequences of fatigue rather than causes. The study was not designed to validate whether these gene profiles predict clinical outcomes or treatment response. Results cannot be generalized to male patients or to different populations, and findings require replication in independent cohorts before clinical application.
Tags
Symptom:Fatigue
Biomarker:Gene Expression
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.2217/14622416.7.3.375
- PMID
- 16610948
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →